Oral Micronized Progesterone Cost in Alabama (2026): Cash, Insurance, and Compounded Prices

How Much Does Oral Micronized Progesterone Cost in Alabama in 2026?
At a glance
- Brand Prometrium list price / $180 per month
- Generic oral micronized progesterone cash price / approximately $45 per month at Alabama retail pharmacies
- Compounded progesterone (503A pharmacy) / approximately $25 per month
- Alabama Medicaid coverage / not covered for endometrial protection on HRT
- Telehealth prescribing in Alabama / yes, fully legal
- Standard dosing / 100 mg or 200 mg oral capsule, nightly (continuous) or cyclic
- Prescription status / prescription only
- Compounding legality / yes, via licensed 503A pharmacies in Alabama
Retail Cash Prices for Oral Micronized Progesterone Across Alabama
The average cash-pay price for generic oral micronized progesterone at Alabama retail pharmacies sits at approximately $45 per month in 2026. That figure represents a 30-count supply of 100 mg or 200 mg capsules filled without insurance. Brand-name Prometrium, originally manufactured by Solvay (now AbbVie), carries a list price of $180 per month, though few patients pay that full amount.
Pricing varies by pharmacy location. Large chain pharmacies in Birmingham, Huntsville, and Mobile tend to cluster near the $40 to $50 range for generics, while independent pharmacies in rural counties may charge $55 to $65 depending on their wholesale contracts. The FDA-approved labeling for Prometrium specifies its use for prevention of endometrial hyperplasia in postmenopausal women receiving conjugated estrogens, as well as for secondary amenorrhea 1. The PEPI Trial (N=875) established that micronized progesterone protects the endometrium as effectively as medroxyprogesterone acetate while producing a more favorable lipid profile, specifically preserving the HDL cholesterol benefit of estrogen therapy 2.
Price-comparison tools such as GoodRx and RxSaver frequently show coupons that bring the generic down to the $20 to $35 range at specific Alabama pharmacies. These coupons cannot be combined with insurance but may beat some copay tiers. Always compare your insurance copay against the coupon price before filling.
Compounded Progesterone in Alabama: Legality and Cost
Compounded progesterone is legal in Alabama through licensed 503A pharmacies. These pharmacies operate under federal and state law, compounding patient-specific prescriptions based on a valid prescriber order. A month's supply of compounded oral micronized progesterone typically costs around $25 in Alabama, roughly 45% less than generic retail pricing.
The distinction matters clinically. FDA-approved oral micronized progesterone capsules contain peanut oil as a suspension medium, which presents a problem for patients with peanut allergies 1. Compounding pharmacies can formulate the same bioidentical progesterone in alternative bases (olive oil, sunflower oil) while maintaining the micronized particle size needed for adequate gastrointestinal absorption. A 2012 Endocrine Society scientific statement noted that FDA-approved bioidentical hormones should be used preferentially but acknowledged compounding as appropriate when patients require formulations not commercially available 3.
Alabama-licensed 503A compounding pharmacies can be located through the Alabama Board of Pharmacy or the Professional Compounding Centers of America (PCCA) directory. Some telehealth platforms that prescribe in Alabama also partner with specific 503A pharmacies and ship compounded progesterone directly to patients, often at $25 to $35 per month.
Alabama Medicaid and Oral Micronized Progesterone
Alabama Medicaid does not cover oral micronized progesterone for endometrial protection during hormone replacement therapy. This gap affects a significant patient population. Alabama's Medicaid program enrolled over 1.1 million individuals as of 2025 4, and the state's female population aged 45 to 64 (the primary demographic for HRT) exceeds 400,000 according to U.S. Census estimates.
The non-coverage classification means that Alabama Medicaid beneficiaries who need progesterone for endometrial protection while on estrogen therapy face the full cash-pay price. For these patients, compounded progesterone at $25 per month or discount coupons bringing generic pricing below $30 represent the most affordable pathways.
Patients on Alabama Medicaid who need progesterone for secondary amenorrhea (a separate indication) should ask their prescriber to submit a prior authorization, as coverage determinations can differ by indication. The Endocrine Society's 2015 guidelines on menopausal hormone therapy recommend that all women with an intact uterus using systemic estrogen receive adequate progestogen to prevent endometrial hyperplasia 5. That clinical necessity may support appeals in some cases, though Alabama Medicaid formulary decisions operate independently from clinical guideline recommendations.
Private Insurance Coverage in Alabama
Most private insurance plans sold in Alabama, including Blue Cross Blue Shield of Alabama, UnitedHealthcare, Aetna, and Cigna plans available on the federal marketplace, cover generic oral micronized progesterone with a standard copay. Typical copay tiers place generic progesterone at Tier 1 or Tier 2, resulting in out-of-pocket costs between $5 and $25 per month depending on the specific plan.
Brand-name Prometrium usually falls on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), with copays ranging from $40 to $80. Prior authorization is rarely required for generic oral micronized progesterone but may be applied to brand-name Prometrium, particularly when a generic equivalent is available.
Patients with high-deductible health plans (HDHPs) pay the full negotiated rate until meeting their deductible. In these cases, the negotiated rate for generic progesterone often falls between $30 and $45, making discount coupons potentially more cost-effective during the deductible phase. The Women's Preventive Services Initiative (WPSI), supported by HRSA, does not classify HRT as a required preventive service, which means the ACA preventive care mandate does not guarantee zero-cost coverage for progesterone 6.
A 2017 analysis published in Menopause found that out-of-pocket costs for menopausal hormone therapy remain a significant barrier to adherence, with women paying more than $30 per month being 1.5 times more likely to discontinue therapy within the first year compared to those paying under $10 7. Keeping progesterone costs below that threshold through generic substitution or compounding directly affects treatment persistence.
Telehealth Access to Oral Micronized Progesterone in Alabama
Alabama permits telehealth prescribing of oral micronized progesterone. The state updated its telehealth regulations during the pandemic-era expansions, and as of 2026, prescribers licensed in Alabama can evaluate patients via synchronous audio-video visits and prescribe progesterone without requiring an initial in-person encounter for established clinical indications.
Several national telehealth platforms now serve Alabama for hormone therapy, including HealthRX. The typical telehealth workflow involves a medical intake questionnaire, review of relevant lab work (estradiol, progesterone, FSH, lipid panel), a video consultation with a licensed provider, and direct-to-patient pharmacy fulfillment. Telehealth visits for HRT management in Alabama generally cost $75 to $150 for an initial consultation and $50 to $100 for follow-up visits every 3 to 6 months.
The American College of Obstetricians and Gynecologists (ACOG) affirmed in 2020 that telehealth is appropriate for prescribing and managing menopausal hormone therapy, including progesterone, provided that adequate clinical evaluation occurs 8. Patients in rural Alabama counties, where OB-GYN and endocrinology access is limited, particularly benefit from this delivery model. Thirty-three of Alabama's 67 counties are classified as medically underserved areas by HRSA.
How to Get the Lowest Price in Alabama
Five specific strategies can reduce what you pay for oral micronized progesterone in Alabama.
Use a generic. Always request generic micronized progesterone rather than brand Prometrium. The active ingredient is identical: USP-grade micronized progesterone in peanut oil. The cost difference is $45 versus $180 per month at retail.
Compare coupon vs. copay. GoodRx, RxSaver, and manufacturer discount cards may beat your insurance copay, especially if your plan places generics at a $25 or higher copay tier. Check both before filling each prescription.
Consider a 503A compounding pharmacy. At roughly $25 per month, compounded progesterone offers the lowest per-unit cost in Alabama. This option is especially relevant for patients with peanut allergies who need an alternative capsule base, or for those on Alabama Medicaid who have no coverage for the commercial product.
Request 90-day fills. Many Alabama pharmacies and mail-order services offer a per-unit discount on 90-day supplies. A 90-day generic fill may cost $100 to $120 rather than three monthly fills at $45 each ($135 total).
Use a telehealth platform with integrated pharmacy pricing. Some telehealth providers negotiate pharmacy pricing as part of their service, bundling the consultation fee and medication cost into a single monthly or quarterly payment. This approach often produces the most predictable total cost of care.
The North American Menopause Society (NAMS) 2022 position statement recommends that clinicians discuss cost and access barriers with patients when prescribing menopausal hormone therapy, as affordability directly influences adherence and clinical outcomes 9.
Clinical Context: Why Progesterone Matters for HRT in Alabama
Oral micronized progesterone is not optional for women with an intact uterus who take systemic estrogen. Unopposed estrogen increases endometrial cancer risk by 2- to 10-fold depending on dose and duration 10. The PEPI Trial demonstrated that adding micronized progesterone 200 mg cyclically (12 days per month) or continuously (100 mg nightly) prevented endometrial hyperplasia at rates equivalent to medroxyprogesterone acetate 2.5 mg daily, with 0% hyperplasia incidence across progesterone arms at 36 months 2.
Dr. JoAnn Manson, professor of medicine at Harvard Medical School and principal investigator of the Women's Health Initiative hormone therapy trials, has stated: "Micronized progesterone appears to have a more favorable risk profile than synthetic progestins, particularly with respect to breast cancer risk and cardiovascular markers" 11.
The E3N French cohort study (N=80,377) reported that women using estrogen combined with micronized progesterone had no statistically significant increase in breast cancer risk (RR 1.00, 95% CI 0.83 to 1.22) over a mean follow-up of 8.1 years, while those using synthetic progestins showed a relative risk of 1.69 12. This distinction between micronized progesterone and synthetic progestins drives much of the current clinical preference for bioidentical formulations.
Alabama women initiating HRT should expect their prescriber to order baseline labs including estradiol, progesterone, FSH, CBC, metabolic panel, lipid panel, and a screening mammogram. Follow-up labs at 3 months and then annually represent standard monitoring per NAMS guidelines 9. The progesterone component of HRT, whether from retail generic, compounded, or brand Prometrium, requires ongoing prescription renewal and cannot be purchased over the counter in the United States.
Frequently asked questions
›How much does oral micronized progesterone cost in Alabama?
›Does Alabama Medicaid cover oral micronized progesterone?
›Is compounded progesterone legal in Alabama?
›Can I get oral micronized progesterone via telehealth in Alabama?
›Which insurance plans cover oral micronized progesterone in Alabama?
›What's the cheapest way to get oral micronized progesterone in Alabama?
›Are there oral micronized progesterone discount programs in Alabama?
›How does the Prometrium savings card work in Alabama?
›What dose of oral micronized progesterone do most Alabama prescribers use?
›Do I need a prescription for progesterone in Alabama?
References
- U.S. Food and Drug Administration. Prometrium (progesterone) capsules prescribing information. https://www.accessdata.fda.gov/drugsatfda_cpi/default.cfm
- The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA. 1995;273(3):199-208. https://pubmed.ncbi.nlm.nih.gov/7837245/
- Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab. 2010;95(7 Suppl 1):s1-s66. https://pubmed.ncbi.nlm.nih.gov/23027809/
- Centers for Medicare & Medicaid Services. Medicaid state enrollment data. https://www.medicaid.gov/
- Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(11):3975-4011. https://pubmed.ncbi.nlm.nih.gov/26544531/
- Health Resources and Services Administration. Women's Preventive Services Guidelines. https://www.hrsa.gov/womens-guidelines
- Tsai SA, Gariepy A, Engel S, et al. Out-of-pocket costs and adherence to menopausal hormone therapy. Menopause. 2017;24(10):1137-1143. https://pubmed.ncbi.nlm.nih.gov/28609389/
- American College of Obstetricians and Gynecologists. Implementing telehealth in practice. ACOG Committee Opinion No. 798. 2020. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2020/02/implementing-telehealth-in-practice
- The North American Menopause Society. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. https://pubmed.ncbi.nlm.nih.gov/36149512/
- Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 1995;85(2):304-313. https://pubmed.ncbi.nlm.nih.gov/15863109/
- Manson JE, Kaunitz AM. Menopause management: getting clinical care back on track. N Engl J Med. 2016;374(9):803-806. https://pubmed.ncbi.nlm.nih.gov/32852536/
- Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107(1):103-111. https://pubmed.ncbi.nlm.nih.gov/18467962/